Korro Bio (KRRO) Operating Expenses (2018 - 2026)
Korro Bio's (KRRO) quarterly Operating Expenses came in at $20.4 million in Q1 2026, down 25.88% YoY from $27.6 million in Q1 2025, and down 60.46% on a QoQ basis from $51.7 million in Q4 2025.
Korro Bio (KRRO) Operating Expenses (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Operating Expenses data on file, last reported at $20.4 million in Q1 2026.
- Quarterly Operating Expenses fell 25.88% year-over-year to $20.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $121.1 million (up 20.75% YoY) and the FY2025 annual result came in at $128.2 million, up 36.17% from the prior year.
- Operating Expenses slipped to $20.4 million in Q1 2026, from $51.7 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $51.7 million in Q4 2025 to a low of -$5.8 million in Q4 2022.
- A 5-year average of $22.7 million and a median of $21.5 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses plunged 127.19% — and 2023, when it jumped 563.03%.
- Tracing KRRO's Operating Expenses over 5 years: stood at -$5.8 million in 2022, then jumped by 563.03% to $26.9 million in 2023, then slipped by 5.88% to $25.3 million in 2024, then jumped by 104.21% to $51.7 million in 2025, then slumped by 60.46% to $20.4 million in 2026.
- The last three Operating Expenses figures came in at $20.4 million (Q1 2026), $51.7 million (Q4 2025), and $20.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Korro Bio | 228.60 Mn | 113.56 Mn | - | 20.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.11 Mn |
| Mar 31, 2026 | 20.44 Mn |
| Dec 31, 2025 | 51.69 Mn |
| Sep 30, 2025 | 20.33 Mn |
| Jun 30, 2025 | 28.66 Mn |
| Mar 31, 2025 | 27.57 Mn |
| Dec 31, 2024 | 25.31 Mn |
| Sep 30, 2024 | 23.29 Mn |
| Jun 30, 2024 | 24.13 Mn |
| Mar 31, 2024 | 21.45 Mn |
| Dec 31, 2023 | 26.89 Mn |
| Sep 30, 2023 | 19.15 Mn |
| Jun 30, 2023 | 18.41 Mn |
| Mar 31, 2023 | 20.09 Mn |
| Dec 31, 2022 | -5.81 Mn |
| Sep 30, 2022 | 20.28 Mn |
| Jun 30, 2022 | 21.27 Mn |
| Mar 31, 2022 | 23.26 Mn |
| Dec 31, 2021 | 21.36 Mn |
| Sep 30, 2021 | 24.99 Mn |